Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher

Artificial Intelligence ( AI ) has received incredible attention this year due to the public release of OpenAI's  ChatGPT. Its profound capabilities have successfully captured the imaginations of a swath of audiences from technology enthusiasts and investors to social commentators.

When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong

Johnson & Johnson is cutting its drug development efforts for infectious diseases. It hasn't said anything about ceasing sales of its products on the market.

Johnson & Johnson Just Cut an Entire Division. Is It Still a Buy?

3M and Johnson & Johnson have been increasing their dividend payments for decades. They offer above-average dividend yields, with 3M paying as much as 6%.

2 Dividend Kings That Face Massive Legal Risks

Three of Johnson & Johnson's blockbusters are on Medicare's price negotiation list. Drugmakers have filed court cases fighting the government's plan to directly negotiate prices.

Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?

Amgen

AstraZeneca

Bristol-Myers

Eli Lilly

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

McDonald's

Occidental Petroleum

Dividend stocks provide essential passive income for many investors. For those heading into retirement, this is especially true.

Set and Forget: 3 Dividend Stocks Perfect for Your IRA

Merck

Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.

Medicare drug price negotiations may have a muted impact on drugmakers in the near term

Johnson & Johnson (JNJ) on Wednesday released its first earnings forecast as a standalone pharmaceutical and medical devices company, estimating double-digit growth in earnings this year.

Johnson & Johnson Forecasts Double-Digit Earnings Growth After Kenvue Spin-Off

Medicare's First Price Negotiation List Targets Expensive Drugs

Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tuberculosis group said on Wednesday.

J&J, India's Lupin cut prices for tuberculosis drug in lower-income countries

Kenvue

Johnson & Johnson (NYSE:JNJ) has released new financial results for previous quarters that strip out the consumer-health unit that was recently hived off into a new company called Kenvue. J&J, which is now focused on its pharmaceutical and medical-technology businesses, said second-quarter sales were $21.52 billion, up 6.5% from a year ago.

Johnson & Johnson sets out new guidance after Kenvue split

Johnson & Johnson maintains its quarterly dividend of $1.19 a share after spinning out consumer-health company Kenvue, although it lowers its earnings and sales projections.

Johnson & Johnson Maintains Dividend After Kenvue Spinout

Johnson & Johnson JNJ, +0.01% updated on Wednesday its 2023 financial guidance in the wake of the Kenvue Inc. KVUE, -0.48% separation that was completed last week. The drug maker now expects full-year reported sales of $83.2 billion to $84.0 billion, down from previous guidance of $98.8 billion to $99.8 billion.

J&J revises 2023 sales, profit outlook lower after Kenvue separation, will maintain dividend

Johnson & Johnson on Wednesday forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue.

J&J forecasts 12.5% growth in 2023 profit after Kenvue spinoff

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (“the Company”) today announced updates to its financials and 2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The Company has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance found in this release, which may be accessed by visiting the Investors section of the Company's websit.

Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation

The Biden Administration just announced the 10 drugs that will be first included in Medicare price negotiations. Several big drugmakers could be affected, with Johnson & Johnson and Bristol Myers Squibb at the top of the list.

What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?

J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.

J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer

The Biden administration unveiled the much-awaited list officially kicking off a process that aims to control rising drug costs in the U.S.

Here are the three most used drugs on the Medicare price negotiation list

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

Novo Nordisk

Novartis

We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.

10 Drugs Selected for Medicare Price Reduction

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

AbbVie

Pfizer

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

American Express

Costco

Disney

Coca-Cola

Blue-chip stocks have long been “buy and hold” firms with a dominant position in their industry. While they often lack the growth potential of their tech or growth stock peers, they make up for it with stability and reliability.

The 7 Most Promising Blue-Chip Stocks to Own Now

Kroger

Philip Morris

Sempra Energy

Exxon Mobil

While hanging up the boots may be a concept that's decades away for some of you, it's never too early to start targeting retirement stocks to buy. Of course, if you're younger, you have the luxury of time to take some risks.

7 Reliable Retirement Stocks to Secure a Golden Future

J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.

News for Johnson & Johnson Stock (JNJ)